Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Cytogenetic risk stratification in FLT3-mt NPM1-negative AML undergoing alloSCT in remission

Arnon Nagler • 1 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the role of cytogenetic risk stratification in FLT3-mutated NPM1-negative patients with AML undergoing allogeneic stem cell transplantation (alloSCT) in remission. In these patients, cytogenetic risk is significantly associated with outcome and therefore an important prognosticator in FLT3-mutated, NPM1-negative AML patients undergoing alloSCT. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Arnon Nagler

Molecular profiling and MRD are reshaping transplant decision-making in AML
3:19
Molecular profiling and MRD are reshaping transplant decision-making in AML
Arnon Nagler • 15 Jun 2026
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
3:26
EBMT analysis: alloSCT may overcome FLT3-ITD risk in CBFB::MYH11-positive AML
Arnon Nagler • 15 Jun 2026
Targeted therapies and immunotherapy are redefining transplantation in AML
3:18
Targeted therapies and immunotherapy are redefining transplantation in AML
Arnon Nagler • 15 Jun 2026
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
2:40
Umbilical cord blood transplantation in adults: revisiting its role in modern practice
Arnon Nagler • 15 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals